When caring for critically ill patients, do clinicians have a responsibility to be innovative and try unproven approaches when accepted approaches are failing?

Respiratory Care

Volumn 52, Issue 4, 2007, Pages 408-413

  Rubin, Bruce K ^a   Steinberg, Kenneth P ^b  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Adventurism; Clinical research; Clinical trials; Ethics; Evidence based medicine; FDA; Food and Drug Administration; Investigational drugs; Patient safety

Indexed keywords

NEW DRUG;

CLINICAL TRIAL; CONFERENCE PAPER; CRITICALLY ILL PATIENT; DRUG APPROVAL; DRUG SAFETY; EVIDENCE BASED MEDICINE; EXPERIMENTAL THERAPY; FOOD AND DRUG ADMINISTRATION; GOOD CLINICAL PRACTICE; HUMAN; INTENSIVE CARE; INTENSIVE CARE UNIT; LAW; MEDICAL DECISION MAKING; MEDICAL ETHICS; MEDICAL SPECIALIST; MORALITY; PATIENT SAFETY; RESPONSIBILITY; TREATMENT FAILURE; ARTICLE; CRITICAL ILLNESS; DECISION MAKING; ETHICS; LEGAL ASPECT; PATIENT RIGHT; TERMINALLY ILL PATIENT; UNITED STATES;

CRITICAL ILLNESS; DECISION MAKING; DRUG APPROVAL; DRUGS, INVESTIGATIONAL; EVIDENCE-BASED MEDICINE; HUMANS; INTENSIVE CARE; INTENSIVE CARE UNITS; PATIENT RIGHTS; TERMINALLY ILL; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 34250613179     PISSN: 00201324     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (12)

1. Thompson L. Experimental treatments? Unapproved but not always unavailable. [Internet]. FDA Consumer Magazine; Jan-Feb 2000. Available at http://www.fda.gov/fdac/features/2000/100-exp.html (Accessed Feb 27, 2007
2. Committee on Quality of Health Care in America, Institute of Medicine. Crossing the quality chasm: a new health system for the 21st century. Washington DC: National Academy Press; 2001.
3. Sackett DL, Rosenberg WM, Gray JA, Haynes RB, Richardson WS. Evidence based medicine: what it is and what it isn't (editorial). BMJ 1996;312(7023):71-72.
4. Sackett DL, Richardson WS, Rosenberg W, Haynes RB. Evidence-based medicine: how to practice and teach EBM, 2nd ed. London: Churchill Livingstone; 2000.
5. Amalberti R, Auroy Y, Berwick D, Barach P. Five system barriers to achieving ultrasafe health care. Ann Intern Med 2005;142(9):756-764. (Pubitemid 40593778)
6. Grol R, Grimshaw J. From best evidence to best practice: effective implementation of change in patients' care. Lancet 2003;362(9391):1225-1230. (Pubitemid 37255352)
7. Muir Gray JA. Evidence-based healthcare: how to make health policy and management decisions, 2nd ed. London: Churchill Livingstone; 2001.
8. Rubenfeld GD. Understanding why we agree on the evidence but disagree on the medicine. Respir Care 2001;46(12):1442-1449. (Pubitemid 33759927)
9. United States et al v Rutherford et al (certiorari to the United States Court of Appeals for the Tenth Circuit). US v Rutherford, 442 US 544, 1979.
10. Okie S. Access before approval: a right to take experimental drugs? N Engl J Med 2006;355(5):437-440.
11. Society for Clinical Trials Board of Directors. The Society for Clinical Trials opposes US legislation to permit marketing of unproven medical therapies for seriously ill patients. Clin Trials 2006;3(2):154-157.
12. Yates JW. Food and Drug Administration, partner in drug development (editorial). CA Cancer J Clin 2006;56(6):321-322.